MPM Capital-backed CODA Biotherapeutics completed the acquisition of Attenua.

MPM Capital-backed CODA Biotherapeutics, a preclinical-stage biopharmaceutical company, completed the acquisition of Attenua, a pharmaceutical company developing antitussive medications. Financial terms were not disclosed. "We are fortunate to be able to acquire these three small molecule therapeutics that have a tremendous amount of high-quality drug development work already completed, one with a currently active IND. Prior to the acquisition, our team has engineered several chemogenetic ion channel receptors that can be specifically controlled by these clinical stage drugs. The robust data packages accompanying these assets will decrease time, cost, and risks as we move toward human clinical trials where we hope to demonstrate transformative results for patients," Michael Narachi, CODA President and CEO.